Assessing the impact of lighting on multiple myeloma patients undergoing stem cell transplantation
Official title: Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Run by Icahn School of Medicine at Mount Sinai · NCT05737732 · Data updated 2026-11-12
This study is testing if better lighting in hospital rooms can help multiple myeloma patients feel better and recover more effectively during their stem cell transplant.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Status | Recruiting |
| Started | February 13, 2023 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | June 12, 2026 |
| Trial ID | NCT05737732 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 21 and older with a diagnosis of multiple myeloma scheduled for their first autologous stem cell transplant.
✕Probably not a fit
Patients with previous stem cell transplants, severe psychological impairments, or active infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multi-site randomized control trial aims to evaluate how systematic lighting affects circadian rhythm, inflammation, neutropenic fever, and symptom burden in multiple myeloma patients undergoing autologous stem cell transplantation. A total of 200 participants will be assigned to receive either circadian-effective or circadian-ineffective lighting in their hospital rooms. Over a 2-month period, the study will measure sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels, and overall symptom burden. The goal is to determine if improved lighting can enhance patient outcomes during a critical treatment phase.
Why it matters
Potential benefit: If successful, this study could lead to improved sleep quality and reduced complications for multiple myeloma patients undergoing stem cell transplantation.
How similar studies have gone: While the specific approach of using lighting for circadian rhythm alignment in this context is novel, similar studies have shown promising results in other patient populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multiple Myeloma diagnosis * Scheduled to undergo their first Autologous Stem Cell Transplant procedure. * 21years or older * Able to provide informed consent. * English-language proficient Exclusion Criteria: * Previous Autologous Stem Cell Transplant procedure * Pregnancy * Eye diseases which limit the ability of light to be processed * Secondary cancer diagnosis within the last 5 years * Severe sleep disorders * History of bipolar disorder or manic episodes * Severe psychological impairment * Previous use of light therapy * Active infection including COVID-19 infection
Where it's running
-
Icahn Schoool of Medicine at Mount Sinai
New York, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Mariana Figueiro, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Barbara Plitnick, BSN
- Email: Barbara.Plitnick@mountsinai.org
- Phone: 518 242-4603
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.